Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7970712 | 0.90 | NPC1 (0.62) | NPC1RAB9ALTA4HHDAC3NCOR2 | |
| Hydrochloric Acid SCHEMBL7442086 | 0.89 | NPC1 (0.61) | NPC1RAB9ALTA4HHDAC3NCOR2 | |
| Trifluoroacetic Acid SCHEMBL7267200 | 0.84 | NPC1 (0.49) | NPC1RAB9AHDAC3NCOR2EGFR | |
| SCHEMBL8691537 | 0.80 | NPC1 (0.59) | NPC1RAB9AHDAC3CES1 | |
| SCHEMBL7981993 | 0.80 | HDAC3 (0.64) | NPC1RAB9ALTA4HHDAC3NCOR2 | |
| Trifluoroacetic Acid SCHEMBL7758264 | 0.80 | MEN1 (0.49) | RAB9ALTA4HMMP2CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL8849659 | 0.79 | ALPI (0.51) | NPC1RAB9ALTA4HCTSC | |
| Trifluoroacetic Acid SCHEMBL7760501 | 0.79 | SMN1; SMN2 (0.52) | LTA4HMMP2CTSCCES1 | |
| Trifluoroacetic Acid SCHEMBL22830136 | 0.78 | ALDH1A1 (0.56) | CYP1A2CES1 | |
| Trifluoroacetic Acid SCHEMBL7760563 | 0.78 | AOC3 (0.60) | RAB9AHDAC3MMP2CYP1A2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676263-B1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2021-10-06 | — | — | EP | disclosed |
| US-11053230-B2 | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. | 2021-07-06 | — | — | US | disclosed |
| US-20200181128-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2020-06-11 | — | — | US | disclosed |
| EP-3426638-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2020-05-06 | — | — | EP | disclosed |
| US-20190055213-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-02-21 | — | — | US | disclosed |
| EP-3426638-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2019-01-16 | — | — | EP | disclosed |
| CN-109071457-A | Inhibitors of indoleamine 2, 3-dioxygenase | 荷兰转化研究中心有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017153459-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-09-14 | — | — | WO | disclosed |
| US-5095137-A | Hypotensives | LABORATORI GUIDOTTI SPA (IT) | 1992-03-10 | — | — | US | disclosed |
| EP-0337348-A2 | Amides of cyclomethylen-1,2-bicarboxylic acids having therapeutical activity, processes for their preparation and pharmaceutical compositions containing them | Laboratori Guidotti S.p.A. (IT) | 1989-10-18 | — | — | EP | disclosed |
| US-4028401-A | (Substituted)ureidoacetohydroxamic acids | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055213-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH2 | NPC1 1264/4885RAB9A 3505/4885LTA4H 1210/4885 |
| US-11053230-B2 | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | NPC1 1419/4885RAB9A 3789/4885LTA4H 1291/4885 |
| US-20200181128-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | NPC1 1419/4885RAB9A 3789/4885LTA4H 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.